Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience-Reference-Cited by-同舟云学术

Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience

Published:2020-10-05 Issue:2 Volume:62 Page:419-427
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Memoli Mara¹²^ORCID,Paviglianiti Annalisa¹,Malard Florent¹³⁴,Battipaglia Giorgia¹⁴,Brissot Eolia¹³⁴,Médiavilla Clémence¹⁴,Bianchessi Antonio¹⁵,Banet Anne¹,Van de Wyngaert Zoé¹,Ledraa Tounes¹,Belhocine Ramdane¹,Sestili Simona¹,Lapusan Simona¹,Hirsch Pierre³⁴⁶,Favale Fabrizia³⁴⁶,Boussaroque Agathe³⁴⁶,Bonnin Agnès¹,Vekhoff Anne¹,Legrand Ollivier¹³⁴,Mohty Mohamad¹³⁴,Duléry Rémy¹³⁴

Affiliation:

1. Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France

2. Department of Medicine and Surgery, Hematology and Hematopoietic Stem Cell Transplant Center, University of Naples Federico II, Naples, Italy

3. INSERM, UMRs 938, Paris, France

4. Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France

5. Department of Molecular Medicine, University of Pavia, Pavia, Italy

6. AP-HP, Service d'Hématologie biologique, Hôpital Saint Antoine, Paris, France

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link